Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Mourad F. Rezk"'
Autor:
Xiaomei Leng, Piotr Leszczyński, Slawomir Jeka, Shengyun Liu, Huaxiang Liu, Malgorzata Miakisz, Jieruo Gu, Lali Kilasonia, Mykola Stanislavchuk, Xiaolei Yang, Yinbo Zhou, Qingfeng Dong, Marian Mitroiu, Janet Addison, Mourad F. Rezk, Xiaofeng Zeng
Publikováno v:
Arthritis Research & Therapy, Vol 26, Iss 1, Pp 1-9 (2024)
Abstract Background Equivalent efficacy and comparable pharmacokinetic, immunogenicity, and safety profiles of the biosimilar BAT1806/BIIB800 and reference tocilizumab (TCZ) in participants with moderate-to-severe rheumatoid arthritis (RA) have been
Externí odkaz:
https://doaj.org/article/7321449214ab450ba0c7e50ae94dea07
Autor:
Hans C. Ebbers, Burkhard Pieper, Amine Issa, Janet Addison, Ulrich Freudensprung, Mourad F. Rezk
Publikováno v:
Rheumatology and Therapy, Vol 6, Iss 3, Pp 317-338 (2019)
Abstract Introduction In 2016, SB4 (Benepali®) became the first etanercept (ETN) biosimilar to obtain marketing authorisation in Europe. Despite robust analytical and clinical comparisons, outstanding questions remain on SB4 use in routine practice.
Externí odkaz:
https://doaj.org/article/4f812e8ff11e4fb88be34d9ccbaedbc7
Autor:
Seenu M. Hariprasad, Richard P. Gale, Christina Y. Weng, Hans C. Ebbers, Mourad F. Rezk, Ramin Tadayoni
Publikováno v:
Ophthalmology and therapy. 11(3)
Biological therapies have revolutionized the treatment of disease across a number of therapeutic areas including retinal diseases. However, on occasion, such treatments may be relatively more expensive compared to small molecule therapies. This can r
Autor:
Mourad F. Rezk, Burkhard Pieper
Publikováno v:
Advances in Therapy. 37:4757-4757